Boehringer Ingelheim and Kansas State University join forces to invest in the future of veterinary medicine

Boehringer Ingelheim’s new agreement with Kansas State University will support the future of animal health and provide resources to students at K-State’s College of Veterinary Medicine.

Boehringer Ingelheim, a leading provider of animal health products, announced a strategic collaboration with Kansas State University’s College of Veterinary Medicine today that will support a strong pipeline of highly skilled veterinarians and continued innovation in the heart of the Kansas City Animal Health Corridor.

Boehringer Ingelheim’s U.S. Animal Health business will donate $800,000 over the next five years to the KSU Foundation. The funds will support interaction and collaboration between Boehringer Ingelheim and veterinary students at one of the leading animal health schools in the country, Kansas State University’s College of Veterinary Medicine.

The collaboration will create opportunities for Boehringer Ingelheim employees to train and present to students, and allow for additional professional development and learning initiatives between Boehringer Ingelheim and the university. As part of the strategic collaboration, Kansas  State University’s College of Veterinary Medicine built a new auditorium named the Boehringer Ingelheim Animal Health Auditorium that was completed in August 2020. The building is now open to students for Fall 2020 classes.

“The Kansas City Animal Health Corridor and Boehringer Ingelheim share a history dating back more than 100 years,” said Randolph Legg, Head of the U.S. Commercial Business for Boehringer Ingelheim Animal Health. “The collaboration with Kansas State University furthers our commitment to this community, where so many of our dedicated employees live and work, and to the future of veterinary medicine.”

“The lives of animals and humans are connected in deep and complex ways. We know that when animals are healthy, humans are healthier, too. It is critically important that we help veterinary students prepare for the changing and growing role vets play in everything from caring for the animals we cherish, to food safety, public health and protecting the environment. This collaboration will help enhance the well-being of both humans and animals to create a healthier tomorrow for our animals, people and our communities.”  

The auditorium is a premier space for student lectures, seminars and campus-wide events, as well as for national meetings for groups such as the student chapter of the American Veterinary Medical Association and the Pre-Vet Symposium. Boehringer Ingelheim will host trainings, symposiums and events in the auditorium, which will expose students to emerging trends in animal health as well as potential career opportunities.

“Boehringer Ingelheim’s belief in preventative care aligns with our commitment to advancing the health of animals through education and research,” said Dr. Bonnie Rush, Dean of College of Veterinary Medicine at Kansas State University.  “We’re thrilled to work with Boehringer Ingelheim to expand our education programs and engagement with the community.”

Boehringer Ingelheim’s largest global animal health manufacturing site is not far from Kansas State University, in nearby St. Joseph, Mo., where the company employs nearly 1,000 people. The site makes more than one billion doses of vaccine a year for livestock producers in the United States and 44 other countries. Boehringer Ingelheim has operated the site in St. Joseph for more than 100 years and has recently invested nearly $50 million to increase manufacturing capacity there.

Boehringer Ingelheim Animal Health 

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both. 

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society- threatening diseases. 

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of $4.5 billion (4 billion euros) in 2019 and a presence in more than 150 countries. 

Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit boehringer-ingelheim.us, facebook.com/BoehringerAHUS or twitter.com/Boehringer_AH.  

Boehringer Ingelheim  

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.  

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. 

In 2019, Boehringer Ingelheim achieved net sales of $21.3 billion (19 billion euros). Our significant investment of over $3.9 billion (3.5 billion euros) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.   

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.  

More information about Boehringer Ingelheim can be found at boehringer-ingelheim.com or in our annual report:  annualreport.boehringer-ingelheim.com.  

About Kansas State University

Kansas State University’s College of Veterinary Medicine is committed to a professional degree program with broad training opportunities across a comprehensive range of companion and exotic animals, and livestock species. Their focus is on initiatives that address important societal needs at a local, national and global level. Kansas State University is located in the animal corridor and is dedicated to the advancement of health and welfare of animals, people, the environment, and the veterinary profession through excellence in teaching, research, service and outreach.

In addition, the National Bio and Agro-defense Facility (NBAF), a $1.25 billion biosafety level-4 laboratory, will replace the current Plum Island Animal Disease Center located in New York, and will be housed adjacent to the Kansas State University campus and College of Veterinary Medicine, with a targeted opening date of 2022-2023.

As Kansas State University’s strategic partner for philanthropy, the KSU Foundation inspires and guides philanthropy toward university priorities to boldly advance K-State family. Visit www.ksufoundation.org for more information.

I am interested in these topics

Contact a gift officer

Joan Burton

Joan Burton Executive Development Officer - Veterinary Medicine

785-775-2057
joanb@ksufoundation.org

Austin Schilling

Austin Schilling Director of Development - Veterinary Medicine

785-775-2082
austins@ksufoundation.org